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While clinical results indicate the benefit of HER2-targeted treat-
ment, the fact remains that this therapy administered according to
current FDA/EMEA-approved protocols can only cure about 50%
of patients with HER2-positive breast carcinoma (1). Recently
developed technologies in multi-omics analysis, together with a
growing understanding of prognosis and predictive biomarkers,
have provided significant advances in discovering and validating
combination treatments that overcome trastuzumab resistance
in HER2-positive breast cancer. However, several critical issues
remain to be addressed. In this research topic, Herter-Sprie et al.
(2) underscore the relevance of molecular alterations of HER2
that activate this molecule, including small insertions and mis-
sense mutations in the kinase domain, missense mutations in
the extracellular domain, or large deletions of the extracellular
domain in mechanisms of primary and acquired resistance to
anti-HER2 therapeutics. In lung adenocarcinomas, 2–4% present
activating mutations within the kinase domain of ERBB2 analo-
gous to those detected in EGFR and never coexisting with EGFR,
KRAS, or ALK alterations (3–5). Such mutations mainly involve
exon 20 and promote HER2 kinase activity. Another mechanism of
HER2 activation consists in missense substitution clusters in sub-
domain II of the extracellular region with consequent mutation
of residues important for stabilization of disulfide-bonded loops
and formation of constitutively dimerized and activated receptor
(6). Truncated HER2 proteins, which are predominantly found in
breast cancers, derive from lack of substantial parts of the extracel-
lular domain, either from proteolytic shedding of the ectodomain
of the full-length receptor (p95HER2) or alternative mRNA trans-
lation from internal initiation codons (HER2 carboxyl terminal
fragments) [reviewed in Ref. (7)]. In both cases, these forms gener-
ate activated homodimers maintained by intermolecular disulfide
bonds and promote aggressiveness of breast cancer and resistance
to trastuzumab because of the lack of a recognizable epitope.
The existence of activating mutations of ERBB2 and poten-
tial therapeutic options (e.g., afatinib or dacomitinib) to block
their aggressive signal underscores the need for in-depth analy-
sis of diagnostic properties specific for these alterations as part
of clinical HER2 status evaluation before choosing among HER2-
directed therapeutic options. In this context,Sapino and coworkers
(8) present a thorough overview of diagnostic pathology instru-
ments for the HER2 gene and the protein, both at the technical
and interpretational levels. In any given day of routine diagnostic
practice, HER2 scoring depends on the demonstration of HER2
overexpression (by immunohistochemistry) or of HER2 gene
amplification by in situ techniques. Interpretation and reporting
are crucial moments, especially in in situ hybridization, where
amplification of the chromosome 17 centromeric region (CEP17)
has been shown to account for misleadingHER2 FISH results, pre-
cluding anti-HER2-based therapy in some patients. In addition,
heterogeneity of HER2 amplification must be considered in clin-
ical therapeutic decisions, despite pilot results suggesting that a
similar trastuzumab benefit for patients with HER2 amplification,
either diffuse or focal (9). Another major debate surrounds the
presence of full-length and truncated forms of the protein, with
controversial clinical data reported on the therapeutic implications
of these HER2 fragments and calling for the need to pathologically
identify HER2 mutation carriers (10).
Molecular alterations of HER2 and its presence on the tumor
cell membrane endow this oncoprotein with relevant immuno-
logical properties, making it an ideal target antigen for long-term
cancer immunoprevention. As thoroughly described by Lollini
et al. (11), HER2 is a class I oncoantigen with a causal role
in tumor growth and progression and with a cellular localiza-
tion accessible to recognition by T cells and to antibody binding.
In studies to address cancer immunoprevention in HER2 trans-
genic mice harboring both activated (i.e., mutant) and wild-type
rat and human oncogene, Lollini and coworkers (12, 13) devel-
oped antigen-specific cell-based vaccines able to elicit protective
immune responses. Specifically, a triplex vaccine containing the
p185 target antigen combined with two powerful non-antigen-
specific stimuli, IL-12 and allogeneic class I MHC molecules, was
highly protective against mammary tumor onset in HER2 trans-
genic mice. This vaccine also prevented metastatic outgrowth of
tumors in mice bearing lung micrometastases indicating that the
approaches developed for cancer immunoprevention could also
be effective in cancer immunotherapy. Major long-term effects
of vaccination were found to depend on the induction of T cell
cytokines, in particular IFNγ, and of antibodies against the HER2
oncoprotein (14). A variety of immunologically based vaccines,
such as those derived from cell proteins or peptides, DNA and
virus, and dendritic cells, demonstrate the ability to prevent mam-
mary carcinoma in HER2 transgenic mice, suggesting that their
potential usefulness in adjuvant therapy of HER2-positive tumors
to prevent the development of invasive breast cancer from HER2-
positive DCIS as well as of metastases. As described by Marchini
et al. (15), the efficacy of anti-HER2 DNA vaccination has been
widely demonstrated in transgenic cancer-prone mice, which reca-
pitulate several features of human breast cancers. Moreover, DNA
vaccines are stable, relatively inexpensive, and simple to purify in
large quantities, offering distinct advantages over other vaccine
prototypes. Reportedly, the plasmid encoding both the extracel-
lular and transmembrane domains of HER2 proved to be far
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superior to plasmids that only encoded the extracellular domain
(secreted form) or the full-length protein in triggering protective
immunity toward HER2-positive tumors (16). Moreover, the first
390 HER2 amino acids in rat are those responsible for induc-
ing the protective immunity, mainly through anti-HER2 antibody
production. Recently, the use of chimeric DNA vaccines derived
by cloning the human cDNA fragment that encodes the first 390
NH2-terminal residues into the rat EC5-TM cut-down plasmid to
regenerate the whole extracellular domain (HuRT) or by cloning
the first 410 NH2-terminal rat residues into the remaining residues
from human HER2 (RhuT) showed superior performance in
breaking tolerance to the HER2 self-antigen (17, 18). Preclinical
data obtained with these chimeric DNA vaccines have provided
the rationale for their use in an ongoing Phase I clinical trial.
Overall, while the benefit of anti-HER2 therapies demonstrated
in clinical trials indicates that HER2 is, to date, one of the most
useful molecules for targeted therapy, optimization of these thera-
pies for HER2-positive cancer patients awaits further studies. The
issues considered in this Research Topic point to the need to bet-
ter define the role of activating molecular alterations of HER2;
refine HER2 clinical testing to design the most tailored treatment
for breast cancer patients; and tailor anti-HER2 vaccines to pre-
vent relapse in high-risk breast cancer patients or progression in
patients with HER2-overexpressing minimal residual disease.
Such knowledge will also be highly relevant in considering the
ability of new HER2-targeted drugs, i.e., the monoclonal anti-
body pertuzumab, the tyrosine kinase inhibitor lapatinib, and
the antibody–drug conjugated trastuzumab-DM1, to improve the
therapeutic effects of trastuzumab. While these new drugs also tar-
get HER2, it is not yet known whether activating HER2 mutations
are sensitive to novel strategies. In view of recent results obtained
in different clinical trials indicating that combining two anti-
HER2 drugs with chemotherapy is the most effective treatment
modality for HER2-positive patients (19), HER2 clinical testing to
select patients for such treatments might be reconsidered. Indeed,
the improved therapeutic benefit of combined anti-HER2 drugs
might result in a lower threshold of oncoprotein expression levels
than that required to obtain benefit from trastuzumab treatment.
Finally, despite the improvements achievable with new anti-HER2
strategies, clinical practice shows that primary and/or acquired
resistance to anti-HER2 strategies remains a relevant issue. Thus,
development of effective vaccines for HER2-positive breast car-
cinoma to be used in addition to or integrated with already
available drugs in patients with low-tumor burden and not heavily
pretreated continues to be a distinct challenge.
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